Ferumoxytol - PharmaKB

Feraheme, Rienso(ferumoxytol)

Feraheme, Ferumoxytol, Rienso (ferumoxytol) is an unknown pharmaceutical. Ferumoxytol was first approved as Feraheme on 2009-06-30. It is used to treat iron-deficiency anemia in the USA. It has been approved in Europe to treat anemia and chronic kidney failure.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
urogenital diseases	D000091642
hemic and lymphatic diseases	D006425
nutritional and metabolic diseases	D009750
signs and symptoms pathological conditions	D013568

Trade Name

FDA

EMA

Feraheme, Ferumoxytol

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Ferumoxytol

Tradename	Company	Number	Date	Products
FERAHEME	Covis Pharma	N-022180 RX	2009-06-30	1 products, RLD, RS

Labels

FDA

EMA

Brand Name	Status	Last Update
feraheme	New Drug Application	2022-06-13
ferumoxytol	ANDA	2022-06-27

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
iron-deficiency anemia	HP_0001891	D018798	D50

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

No data

HCPCS

Code	Description
Q0138	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
Q0139	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)

Clinical

Clinical Trials

114 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Anemia	D000740	HP_0001903	D64.9	2	3	16	5	2	27
Iron-deficiency anemia	D018798	HP_0001891	D50	—	3	12	6	3	24
Iron deficiencies	D000090463	—	—	—	3	12	6	3	24
Chronic renal insufficiency	D051436	—	N18	1	1	6	3	1	12
Kidney diseases	D007674	EFO_0003086	N08	1	1	6	3	1	12
Inflammation	D007249	MP_0001845	—	1	3	1	1	2	7
Atherosclerosis	D050197	EFO_0003914	I25.1	1	—	—	1	2	4
Pancreatic neoplasms	D010190	EFO_0003860	C25	—	—	—	1	1	2
Pregnancy rate	D018873	—	—	—	—	1	1	—	2
Intracranial arteriosclerosis	D002537	EFO_1000860	I67.2	1	—	—	1	—	2

Show 11 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Deficiency diseases	D003677	EFO_1001067	E63	—	—	10	—	2	12
Coronary artery disease	D003324	—	I25.1	—	—	2	—	—	2
Heart transplantation	D016027	EFO_0010673	—	—	1	1	—	—	1
Myocarditis	D009205	—	I51.4	—	1	1	—	—	1
Healthy volunteers/patients	—	—	—	—	1	1	—	—	1

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Brain neoplasms	D001932	EFO_0003833	C71	7	3	—	—	1	11
Neoplasms	D009369	—	C80	5	3	—	—	2	9
Glioblastoma	D005909	EFO_0000515	—	3	1	—	—	2	6
Prostatic neoplasms	D011471	—	C61	2	1	—	—	1	4
Lymphatic metastasis	D008207	EFO_1001364	—	—	1	—	—	2	3
Urinary bladder neoplasms	D001749	—	C67	1	1	—	—	—	2
Aids dementia complex	D015526	EFO_0002608	—	1	1	—	—	—	2
Central nervous system neoplasms	D016543	—	—	—	1	—	—	1	2
Epilepsy	D004827	EFO_0000474	G40.9	—	1	—	—	1	2
Myocardial infarction	D009203	EFO_0000612	I21	—	1	—	—	1	2

Show 26 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Neoplasm metastasis	D009362	EFO_0009708	—	1	—	—	—	2	3
Stroke	D020521	EFO_0000712	I63.9	2	—	—	—	1	3
Multiple sclerosis	D009103	EFO_0003885	G35	2	—	—	—	1	3
Sclerosis	D012598	—	—	2	—	—	—	1	3
Esophageal neoplasms	D004938	—	C15	2	—	—	—	1	3
Breast neoplasms	D001943	EFO_0003869	C50	1	—	—	—	1	2
Triple negative breast neoplasms	D064726	—	—	1	—	—	—	—	1
Hypoxia	D000860	HP_0012418	R09.02	1	—	—	—	—	1
Fetal growth retardation	D005317	EFO_0000495	—	1	—	—	—	—	1
Dental caries	D003731	EFO_0003819	K02	1	—	—	—	—	1

Show 22 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Liver cirrhosis	D008103	EFO_0001422	K74.0	—	—	—	—	2	2
Kidney transplantation	D016030	—	—	—	—	—	—	2	2
Glioma	D005910	EFO_0000520	—	—	—	—	—	2	2
B-cell chronic lymphocytic leukemia	D015451	—	C91.1	—	—	—	—	1	1
Lymphoid leukemia	D007945	—	C91	—	—	—	—	1	1
Skin abnormalities	D012868	HP_0000951	Q82.9	—	—	—	—	1	1
Diabetes mellitus	D003920	HP_0000819	E08-E13	—	—	—	—	1	1
Type 1 diabetes mellitus	D003922	EFO_0001359	E10	—	—	—	—	1	1
Thyroid neoplasms	D013964	EFO_0003841	—	—	—	—	—	1	1
Papillary thyroid cancer	D000077273	—	—	—	—	—	—	1	1

Show 38 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Ferumoxytol
INN	—
Description	Iron(II,III) oxide, or black iron oxide, is the chemical compound with formula Fe3O4. It occurs in nature as the mineral magnetite. It is one of a number of iron oxides, the others being iron(II) oxide (FeO), which is rare, and iron(III) oxide (Fe2O3) which also occurs naturally as the mineral hematite. It contains both Fe2+ and Fe3+ ions and is sometimes formulated as FeO ∙ Fe2O3. This iron oxide is encountered in the laboratory as a black powder. It exhibits permanent magnetism and is ferrimagnetic, but is sometimes incorrectly described as ferromagnetic. Its most extensive use is as a black pigment (see: Mars Black). For this purpose, it is synthesized rather than being extracted from the naturally occurring mineral as the particle size and shape can be varied by the method of production.
Classification	Small molecule
Drug class	—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	—